The third Imperial Confidence in Concept proposal (ICiC3) is bidding for £1M to capitalise on our highly aligned, College-wide emphasis on novel devices, therapeutics and diagnostics. We have previously demonstrated that Imperial has substantially more high quality CiC projects than can be funded from current resources. We have strategically aligned our devolved Research Council Impact Acceleration and Wellcome Trust Institutional Strategic Support funding streams to engage new discovery scientists and promote translation across the Faculties. Through ICiC3, pull-through will be further stimulated via peer translators, technical advisors and alumni supporters. We have expanded our translational base through new partnership with the C&W NHS Trust, while maintaining our collaboration with Imperial Innovations, the NIHR Imperial Biomedical Research Centre (BRC) and the Royal Marsden/Institute of Cancer Research BRC. We are now planning major build on the Imperial West campus, bringing discovery science in Chemistry, Bio-Engineering and Bio-Informatics adjacent to clinical medicine on the Hammersmith campus and dramatically increasing our spin-out incubator capacity. We have consolidated our clinical translational platforms at the Hammersmith into a new Institute of Translational Medicine and Therapeutics (ITMAT), which will promote interaction with Imperial West via BRC project funding. We have continued to expand our ICiC review panel (Chair, Solari) to broaden expertise, with particular attention to diagnostics, devices, bio-engineering and industry. Agreements are in now place with Astra-Zeneca, GSK, Pfizer, MedImmune, UCB, Syncona Partners and J&J for access of selected ICiC projects to high-throughput screening facilities or pump-priming funds. Through sustained evidence of unmet demand, broader partnership, need for longer awards and robust project management,